Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers

Abstract

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.

1 - 97 . (canceled) 
     
     
         98 . A method for formulating an immunogenic composition for treating a cancer situated in a specific organ or tissue in a human patient, comprising:
 selecting at least one bacterial pathogen that is pathogenic in the specific organ or tissue of the patient within which the cancer is situated;   producing an antigenic composition comprising antigenic determinants that together are specific for the bacterial pathogen; and,   formulating the antigenic composition for administration as an immunogenic composition capable of eliciting an immune reaction to treat the cancer in the patient, wherein the antigenic composition is formulated for subcutaneous injection or intradermal injection.   
     
     
         99 . The method of  claim 98 , wherein the organ or tissue is selected from the group consisting of skin, soft tissue, breast, head and neck lymph nodes, axillae/arm lymph nodes, mediastinal lymph nodes, pulmonary hilar lymph nodes, intra-abdominal lymph nodes, inguinal/leg lymph nodes, hematological, bone, meninges, brain, spinal cord, eye/orbit, salivary glands, oral, tonsil, sinus, nasopharynx, thyroid, larynx, trachea, bronchi, lung, pleura, mediastinum, heart, esophagus, stomach, small bowel, colon/rectum, anus, perineum, liver, gallbladder, biliary tract, pancreas, spleen, adrenal gland, kidney, ureter, bladder, peritoneum, retroperitoneal area, prostate, testicle, penis, ovary/adnexae, uterus, cervix, vagina, vulva. 
     
     
         100 . The method of  claim 98 , further comprising killing the bacterial pathogen to formulate the antigenic composition, wherein the antigenic determinants comprise whole dead bacteria. 
     
     
         101 . The method of  claim 98 , further comprising formulating the antigenic composition for administration with an anti-inflammatory. 
     
     
         102 . The method of  claim 101 , wherein the anti-inflammatory is an NSAID. 
     
     
         103 . The method of  claim 98 , wherein the antigenic composition is produced so that the antigenic composition consists essentially of antigenic determinants of one or more bacterial pathogens that are each pathogenic in the specific organ or tissue of the patient within which the cancer is situated. 
     
     
         104 . The method of  claim 100 , wherein the antigenic composition is produced so that the antigenic composition consists essentially of antigenic determinants of one or more bacterial pathogens that are each pathogenic in the specific organ or tissue of the patient within which the cancer is situated. 
     
     
         105 . The method of  claim 98 , wherein the antigenic composition is produced so that the antigenic composition comprises antigenic determinants of a single bacterial pathogen that is the most commonly pathogenic in the specific organ or tissue of the patient within which the cancer is situated. 
     
     
         106 . The method of  claim 100 , wherein the antigenic composition is produced so that the antigenic composition comprises antigenic determinants of a single bacterial pathogen that is the most commonly pathogenic in the specific organ or tissue of the patient within which the cancer is situated. 
     
     
         107 . The method of  claim 98 , wherein the antigenic composition is produced so that the antigenic composition consists essentially of antigenic determinants of a single bacterial pathogen that is the most commonly pathogenic in the specific organ or tissue of the patient within which the cancer is situated. 
     
     
         108 . The method of  claim 100 , wherein the antigenic composition is produced so that the antigenic composition consists essentially of antigenic determinants of a single bacterial pathogen that is the most commonly pathogenic in the specific organ or tissue of the patient within which the cancer is situated.